

**Question for written answer E-002148/2025
to the Commission**
Rule 144
Margarita de la Pisa Carrión (Pfe)

Subject: Implementation of EU legislation to protect healthcare workers from exposure to hazardous medicinal products

Healthcare workers in oncology are often exposed to hazardous medicinal products (HMPs), many with carcinogenic, mutagenic or reprotoxic properties (CMR substances), which poses a serious risk to their health. Since April 2024, Directive (EU) 2022/431 has required the implementation of specific measures, such as the use of closed systems where it is impossible to do away with or replace an HMP. However, shortcomings remain: there is an absence of clear risk assessment protocols, a shortage of adequate protective equipment and insufficient training. Although the Commission published an indicative list of HMPs to facilitate risk assessments on 18 February 2025, this measure is limited if not accompanied by real guarantees of protection for workers.

In light of this situation:

1. Does the Commission consider it necessary to have minimum training criteria and adequate protective equipment for people working with such substances?
2. What technical guidance will the Commission provide on the use of closed systems, with a view to ensuring that workers have effective means to reduce their exposure?

Submitted: 28.5.2025